Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRASPA plus low-dose cytarabine versus low-dose cytarabine in older unfit newly diagnosed AML
2012-002026-78Phase 2Completed
- Sponsor
- PHAXIAM Therapeutics
- Start
- Oct 2013
- Modality
- Small Molecules, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in acute myeloid leukemia (AML) comparing GRASPA plus low-dose cytarabine with Low-dose cytarabine alone (2 arms). Primary endpoint: Progression-free survival. Started Oct 2013; status: completed.
02
Drugs
eryaspasecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2012-002026-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002026-78.